Trial investigators evaluated the prognostic and predictive ability of PAM50 molecular prostate cancer subtypes to guide salvage treatment.

A recent analysis of the NRG-RTOG 0534 "SPPORT" clinical trial evaluated the Luminal B (LumB) molecular subtype using the PAM50 genomic classifier to determine whether tumor biology could help identify patients most likely to benefit from hormone therapy.

npj Breast Cancer - The Breast Cancer Classifier refines molecular breast cancer classification to delineate the HER2-low subtype

Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$VYCT #ASTRO25—Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the prospective, randomized integral biomarker BALANCE trial (NCT03371719) finds that the PAM50 molecular signature predicts which patients with recurrent prostate cancer benefit from …

Abstract. Purpose: Based on the results from SOLTI-PATRICIA trial (NCT02448420) cohorts A/B, a direct comparison with standard-of-care treatments is needed to evaluate the efficacy and safety of palbo...

Purpose Estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (MBC) shows variable outcomes after first-line CDK4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET). The pro...

PAM50 gene expression test identifies which recurrent prostate cancer patients benefit most from hormone therapy with apalutamide.

El análisis denominado PAM50 permitiría a los especialistas identificar perfiles individuales y ajustar las estrategias terapéuticas. Cómo este avance podría modificar el futuro de la terapia personalizada, según expertos consultados por National Geographic

a, A specificity score for each autosomal arm-level copy number gain or loss was calculated for each PAM50 subtype from the TCGA data (top) and each IntCluster from the METABRIC data (bottom) and plotted against the proportion of patients containing that specific arm-level alteration. The specificity score was defined as the proportion of genes on a given chromosome arm, whose percentage of alteration was greater than 1.645 standard deviations above the mean of all subtypes, such that a score of 1 indicates that each gene on a given arm is significantly gained or lost relative to all other subtypes. Arm-level amplifications are shown in red and arm-level losses in blue and selected chromosome arms are labelled. b, Chromosome arm-level alterations were ranked by the product of their specificity score and proportion of basal-like breast cancer patients called by PAM50 subtyping of the TCGA and METABRIC datasets or by IntCluster10 patients from the METABRIC dataset. A higher product represents a greater association for that alteration with basal-like breast cancer relative to the other subtypes and is towards the left of the heatmap. Gains and losses for each arm are indicated in red and blue font above the heatmap, respectively. An inset...